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Cardinal motor features of Parkinson’s disease (PD) include bradykinesia, rest tremor, and rigidity, which appear in the early
stages of the disease and largely depend on dopaminergic nigrostriatal denervation. Intermediate and advanced PD stages are
characterized by motor fluctuations and dyskinesia, which depend on complex mechanisms secondary to severe nigrostriatal loss
and to the problems related to oral levodopa absorption, and motor and nonmotor symptoms and signs that are secondary to
marked dopaminergic loss and multisystem neurodegeneration with damage to nondopaminergic pathways. Nondopaminergic
dysfunction results in motor problems, including posture, balance and gait disturbances, and fatigue, and nonmotor problems,
encompassing depression, apathy, cognitive impairment, sleep disturbances, pain, and autonomic dysfunction.There are a number
of symptomatic drugs for PD motor signs, but the pharmacological resources for nonmotor signs and symptoms are limited, and
rehabilitation may contribute to their treatment. The present review will focus on classical notions and recent insights into the
neuropathology, neuropharmacology, and neurophysiology of motor dysfunction of PD.These pieces of information represent the
basis for the pharmacological, neurosurgical, and rehabilitative approaches to PD.
1. Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease (AD), with
an overall prevalence of 300 per 100,000 [1] that rises from 41
in the 40–49 years’ age range to 1903 in people older than age
of 80 years [2].
PD has been traditionally considered as a puremovement
disorder secondary to focal degeneration of dopaminergic
neurons in the substantia nigra, but, in recent years, the
clinical phenotype has been better illuminated, showing that
PD is a multisystem neurodegenerative disorder with motor
and nonmotor features (Table 1) [3]. Amongmotor symptoms
and signs, the cardinal ones (bradykinesia, rest tremor, and
rigidity) are mainly ascribed to the loss of dopaminergic
neurons [4], but those involving posture, balance, and gait
are largely secondary to degeneration of nondopaminergic
pathways and significantly contribute to impairment and
disability in advanced PD patients [5]. Nonmotor features
result from multiple neurotransmitter deficiencies in the
central and peripheral nervous system [6] and include psy-
chiatric (depression, apathy, hallucinations, and delusions)
and autonomic (constipation, orthostatic hypotension, and
urinary and genital disturbances) features, cognitive impair-
ment (involvement of executive functions, memory, and
visuospatial functions up to dementia) [7, 8], sleep disorders,
olfactory dysfunction, and pain [9] that together contribute
to worsening the quality of life (QoL) and patient’s disability
[6].
Multiple agents have been studied in randomized con-
trolled trials (RCTs) designed to assess disease modification
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or neuroprotection in PD, but all have failed [10], and med-
ical treatment remains symptomatic [10]. Pharmacological
therapy is based on levodopa and dopamine agonists and
is very successful in the early stages of the disease, when
dopaminergic symptoms and signs are predominant and long
term motor complications still have not developed, but other
treatment strategies are almost invariably necessary as time
passes [3]. Long term levodopa-inducedmotor complications
include motor fluctuations and dyskinesia and affect almost
all PD patients at some point during the disease course,
with relevant implications in global health status [11]. Despite
various pharmacological approaches, as well as more invasive
strategies including devices and functional neurosurgery,
being available to manage such complications, many patients
remain significantly disabled, and a fully satisfying manage-
ment of motor complications is still an unmet need of PD
therapy [11]. Nonmotor symptoms and signs are integral to
PD at onset and throughout the disease course, but to date
their treatment is largely unsatisfactory [9].
This review will summarize the evidence on the patho-
physiology of PD motor symptoms and signs and give some
insight into their neuropathological and neuropharmacolog-
ical bases.These pieces of informationmay help the clinicians
to better understand the rationale of current pharmacological
and rehabilitation strategies for PD and encompass the large
areas of uncertainty that should represent the focus for
further studies.
2. The Functional Anatomy and
Pathophysiology of the Basal Ganglia and
the Role of the Cerebellum
Thebasal ganglia (BG) include the striatum, which comprises
the caudate nucleus, putamen, and nucleus accumbens, the
globus pallidus that is divided into an external segment
(GPe) and an internal segment (GPi), the substantia nigra
that can be divided into a pars compacta (SNc) and a pars
reticulata (SNr), and the subthalamic nucleus (STN) [14].
The main input region of the BG is the striatum, which
receives afferents from many regions of the cerebral cortex,
including motor and premotor, cingulate, and prefrontal
cortices, and the intralaminar nuclei of the thalamus [14–16].
The major output regions of the BG are the GPi and the SNr,
which project to the thalamus modulating activity of cortical
regions and to the brainstem [14–16]. The input and output
regions are connected via either the direct or the indirect
pathways, both of which arise from the matrix medium spiny
neurons of the striatum (Figure 1), while the striosomal
medium spiny neurons control dopaminergic projections
from the SNc [14–17]. Corticostriatal projections, intrinsic
BG circuits, and output pathways are functionally arranged
according to the BG loop involved (Figure 2) [16, 17]. The
main neurotransmitter of BG circuit is the inhibitory gamma-
aminobutyric acid (GABA), while neurons of the STN use
excitatory glutamate, and those of the SNc use dopamine
[18]. Despite its oversimplification, the basic BG circuitry and
the balance between the direct and indirect striatal pathways
provide a simple heuristic model for PD cardinal signs and
dyskinesia [16, 17]. According to this model, the pathophysi-
ological hallmark of PD hypokinetic signs is the prevalence
of the indirect pathway over the direct one resulting in
increased neuronal firing activity in the output nuclei of the
BG and leading to excessive inhibition of thalamocortical
and brainstem motor systems, interfering with normal speed
of movement onset and execution (Figure 1) [14–16]. At
variance, overactivity in the direct pathway and imbalance
with the indirect onemay cause reduced inhibitoryBGoutput
and result in reduced BG filtering and parallel facilitation of
multiple movement fragments causing dyskinesia, including
those induced by levodopa in advanced PD [16, 19]. This
model and its prediction of increased STN and GPi activity
in PD fit well with the efficacy of targeting and inhibiting
these two nuclei with deep brain stimulation (DBS), which
represents the gold standard treatment of motor fluctuations
and dyskinesia in advanced PD [20]. Despite its merits, this
model is blinded to a number of experimental and clinical
data, including the following issues: (a) the large number of
BG neurotransmitters, neuromodulators, and their receptors
goes beyond GABA, glutamate, and dopamine [21], and the
complex arrangement of medium spiny neurons in matrix
and striosome [17] does not fit well with a simple direct-
indirect pathway imbalance; (b) the model should go beyond
the simple concept of firing rate and include firing pattern,
synchronization, and coincidence to better understand BG
circuitry functioning; (c) while the model can convincingly
explain bradykinesia, it fails to completely account for the
appearance of rigidity and tremor; (d) pallidotomy or GPi
DBS does not cause hyperkinesia, as predicted by this model,
but may paradoxically reduce PD hyperkinetic signs; (e)
hypokinetic and hyperkinetic signs can coexist in PD patients
and cannot be simply considered as two sides of the same
coin; (f) BG surgery and DBS can be performed with little
or no apparent deficits [16, 22]. Future updated models of BG
functions should incorporate a more complex BG circuitry
and include nonlinear dynamics to address these issues [16].
The BG circuitries play a key role in selecting a motor
program and inhibiting undesired ones and in movement
preparation and execution, but their functions go beyond
the motor system and include crucial functions such as
learning, planning, executive functions, and emotions [14].
According to their connections, BG loops are functionally
subdivided into motor, oculomotor, associative, and limbic
ones (Figure 2) [12, 13, 16].Themotor loop is organized soma-
totopically and according to specific tasks or parts of a motor
sequence [12, 16]. Abnormally synchronized oscillatory activ-
ity in this loop correlates with motor deficit in PD, and its
suppression by dopaminergic therapies, ablative surgery, or
DBSmight provide the basic mechanism for the amelioration
ofmotor impairment [23].The oculomotor circuit is involved
in the control of saccadic and smooth pursuit eye move-
ments, which are abnormal in most PD patients [24]. The
main abnormality consists of saccade hypometria, although
all types (predictive, anticipatory, and memory-guided) of
saccade generation may be involved [24]. Dopaminergic
therapy and DBS of the STN reduce saccade latencies in
parallel with the improvement of hand bradykinesia [25].The
dysfunction of the limbic circuit contributes broadly to some
4 Parkinson’s Disease
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Figure 1: A simplified view of the functional anatomy of the basal ganglia (BG).Themain input and output connections and the basic internal
circuitry of the BG are shown. Here are represented the direct pathway (panel (a)), the indirect pathway (panel (b)), and the alteration of the
balance between the direct and indirect pathways in Parkinson’s disease (panel (c)). Blue arrows show the excitatory glutamatergic pathways,
red arrows indicate the inhibitory GABAergic pathways, and green arrows mark the dopaminergic pathway. CMA: cingulate motor area; D1:
dopamine D1 receptor; D2: dopamine D2 receptor; GPe: external segment of the globus pallidus; GPi: internal segment of the globus pallidus;
MC: primary motor cortex; PMC: premotor cortex; SMA: supplementary motor area; SNc: substantia nigra pars compacta; SNr: substantia
nigra pars reticulata; STN: subthalamic nucleus; VA/VL: ventral anterior/ventrolateral thalamic nuclei.
PD behavioral aspects, which include reward dysregulation
phenomena, emotional blunting [26], and impulse control
disorders secondary to dopaminergic treatment [27]. The
associative loop takes part in prefrontal cognitive functions,
and its impairment is responsible for cognitive inertia and
executive dysfunction in PD [26].
The BG and the cerebellum modulate the activity of
largely overlapping cerebral cortical areas through mul-
tisynaptic loops, which were traditionally assumed to be
anatomically and functionally separate [28]. Recent studies
showed that the dentate nucleus of the cerebellum projects
to the striatum and to the GPe and that the STN has
topographical projections to the cerebellar cortex via the
pontine nuclei [29]. These reciprocal connections between
the BG and the cerebellum, together with neuropathological
changes in the cerebellum, account for the hypothesis that the
cerebellum plays a role in the pathogenesis of PD symptoms
and signs [28]. Functional MRI studies showed hyperac-
tivation or strengthened connectivity in the cerebellum of
PD patients [30], but whether it represents a pathogenetic
or compensatory change is still debated [31]. Converging
pieces of evidence accumulated recently in favor of a role of
the cerebellum in some PD symptoms and signs, including
tremor [32], gait disturbances through its connections with
the pedunculopontine nucleus (PPN) [33], dyskinesia [34],
and nonmotor symptoms, suggesting that the cerebellum
might represent a promising new target for neuromodulation
[28].
3. The Neuropathology of PD
The classical pathologic substrate for PD is the accumulation
of neuronal inclusions composed of 𝛼-synuclein and called
Lewy bodies and neurites and neuronal loss [35]. Neuronal
loss is most marked in the SNc [35], but Lewy bodies in PD
extendwell beyond this region [36]. Based on the distribution
of 𝛼-synuclein pathology, a staging scheme for PD has been
proposed [36]. According to this scheme, neuronal pathology
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Figure 2: The parallel motor, oculomotor, associative, and limbic
circuits of the basal ganglia. ACA: anterior cingulate area; CMA:
cingulate motor area; DLPFC: dorsolateral prefrontal cortex; FEF:
frontal eye fields; GPi: internal segment of the globus pallidus;
LOFC: lateral orbitofrontal cortex; MC: primary motor cortex; MD:
mediodorsal nucleus of the thalamus;MDpl:mediodorsal nucleus of
thalamus, pars lateralis; MOFC: medial orbitofrontal cortex; PMC:
premotor cortex; SEF: supplementary eye field; SMA: supplemen-
tarymotor area; SNr: substantia nigra pars reticulata; VAmc: ventral
anterior nucleus of thalamus, pars magnocellularis; VApc: ventral
anterior nucleus of thalamus, pars parvocellularis; VLa: anterior
ventrolateral nucleus of the thalamus; VLcr: ventrolateral nucleus of
thalamus, pars caudalis, rostral division; VLm: ventrolateral nucleus
of thalamus, pars medialis; VS: ventral striatum [12, 13].
occurs early in the dorsal motor nucleus of the vagus and
the olfactory bulbs, then spreads to the locus coeruleus and
SNc when motor signs appear, later on extends to the basal
forebrain, amygdala, and themedial temporal lobe structures,
and finally affects the convexity cortical areas in final stages
[36]. Although this staging scheme is attractive since it fits
well with the occurrence of nonmotor symptoms and signs
across the clinical course of PD, it has been debated because
it is based on autopsy and not on longitudinal studies, and
it does not always hold true in all the patients [37]. In
addition to a number of brain areas, neuronal loss and 𝛼-
synuclein deposition involve also the peripheral nervous
system, suggesting that PD is a multiorgan disease process,
not merely a disorder of the central nervous system [38].
It has become increasingly evident that PD is a het-
erogeneous disorder in terms of symptoms and signs and
natural history, and, based on cluster analysis, two PD
subtypes have been proposed, namely, tremor-dominant PD
and postural instability and gait difficulty (PIGD) PD [39,
40]. Tremor-dominant PD occurs earlier (20–40 years); it is
often genetic and has good prognosis with slow progression,
good response to levodopa, and motor fluctuations [40]. At
variance, PIGD PD occurs sporadically after the age of 60
years with predominant bradykinesia and rigidity and earlier
occurrence of depression and dementia [40]. Some studies
suggested that the two PD subtypes show neuropathological
differences, which include greater neuronal loss in the SNc,
especially in its lateral portion, and the locus coeruleus, more
severe dopamine loss in the ventral GPi and a larger number
of cortical Lewy bodies in PIGD PD, and more severe loss
of neurons in the midbrain retrorubral A8 field in tremor-
dominant PD [40]. Although these data suggest that PD
subtypes have different neuropathology, they are based on
small autopsy studies, with no available biological markers
that can lend support to this hypothesis in vivo [40].
4. The Neuropharmacology of PD
The neuronal loss and 𝛼-synuclein deposition in the SNc
cause the involvement of dopaminergic neurons, the neu-
ropharmacological hallmark of PD, and the rationale for the
treatment with levodopa and dopamine agonists [35]. PD
symptoms and signs appear only after substantial (i.e., >70%)
degeneration of the SNc neurons, documenting remarkable
compensatory phenomena within the nigrostriatal system
[41].
The neuropathological changes in other brain areas result
in degeneration of nondopaminergic pathways, which con-
tributes to motor and nonmotor PD features. Nondopamin-
ergic neurotransmitters and neuromediators include cholin-
ergic, adenosinergic, glutamatergic, GABAergic, noradren-
ergic, serotonergic, opioidergic, and histaminergic systems
(Table 2) [21]. The relative contribution of each of these
pathways to single motor and nonmotor symptoms and signs
andmotor complications in PD is only partially explored, but
they may represent potential targets for new pharmaceutical
interventions [21]. In recent years, many RCTs have been
completed and are ongoing or planned to explore drugs to
counterbalance the loss of these neurotransmitters (Table 2),
and it has been hypothesized that multiple targeting may be a
more efficacious strategy, especially if they act in a synergistic
manner [21].
Loss of cholinergic neurons in the PPN and the nucleus
basalis of Meynert may contribute to posture and gait signs
and falls through failure in the direct control of spinal cir-
cuitries and the deficits in the attentional processes required
for these tasks [42, 43] and to cognitive impairment [7,
43]. The large aspiny interneurons in the striatum contain
also large quantities of acetylcholine, which interacts with
muscarinic and nicotinic receptors [44]. Centrally acting
cholinesterase inhibitors, such as donepezil and rivastigmine,
which delay acetylcholine degradation and prolong its effect,
are commonly used in AD- and PD-related dementia and
appear to offer promising preliminary results for gait distur-
bances in PD (Table 2) [21].
Adenosine acts with the A
2A receptors, which are located
in the dendritic spines of the medium spiny neurons of the
striatum and counteract the inhibitory action of indirect
dopaminergic D2 receptors with no effect on the excitatory
D1 pathway [21]. Drugs that antagonize A
2A receptor activity
in combination with levodopa have been found to reduce
off time in PD patients with motor fluctuations and improve
on time with dyskinesia without changing the amount of
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Table 2: Nondopaminergic neurotransmitters involved in the pathogenesis of Parkinson’s disease and pharmacological agents potentially
active or tested to counteract their deficit.
Neurotransmitter Site Symptom/sign Drug
Acetylcholine PPN, nucleus basalis of Meynert,
striatum
Posture and gait disturbances, FOG,
cognitive problems
Cholinesterase inhibitors, nicotinic
receptor agonists
Adenosine Striatum Motor fluctuations, dyskinesia Adenosine A2A receptor antagonists,caffeine
GABA GPe, STN Motor fluctuations, dyskinesia GAD gene therapy
Glutamate Striatum, STN Dyskinesia, FOG NMDA receptor antagonists, AMPAreceptor antagonists, mGluNAMs
Histamine Striatum Dyskinesia H
2
receptor antagonists
Noradrenaline GPe, locus coeruleus Balance and gait disturbances,FOG, dyskinesia Methylphenidate, 𝛼2 receptor antagonists
Serotonin Dorsal raphe nucleus, striatum, GP,
SN Motor fluctuations, dyskinesia 5-HT1A receptor antagonists
5-HT1A: serotonin receptor 1A; A2A: adenosine receptor A2; AMPA: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; FOG: freezing of gait;
GABA: gamma-aminobutyric acid; GAD: glutamic acid decarboxylase; GP: globus pallidus; GPe: external segment of the globus pallidus; mGluNAMs:
metabotropic glutamate receptor negative allosteric modulators; NMDA: N-methyl-D-aspartate; PPN: pedunculopontine nucleus; SN: substantia nigra; STN:
subthalamic nucleus.
troublesome peak-dose dyskinesia [45]. Caffeinated coffee
consumption is inversely related to PD risk, suggesting a
possible and largely debated neuroprotective effect of caffeine
and/or effect on motor function [21]. Caffeine is a nonselec-
tive A
2A receptor antagonist that has been found to improve
motor signs in PD in small trials [46], but larger RCTs are
needed to confirm these preliminary findings and to establish
whether they are sustained [21].
5. Pathophysiology of Bradykinesia in PD
The terms bradykinesia, hypokinesia, and akinesia collec-
tively define a group of functional disturbance of volun-
tary movement prominently characterized by slowness [47].
Bradykinesia refers to slowness of movement that is ongoing,
akinesia indicates failure of voluntary, spontaneous (e.g.,
in facial expression), or associated movement (e.g., arm
swing during walking) to occur, and hypokinesia refers
to movements that are smaller than desired, in particu-
lar with repetitive movements [47]. In addition to whole-
body slowness, bradykinesia may impair the fine motor
movements, which is usually demonstrated in PD patients
during rapid alternating movements of fingers, hand, or feet
as a progressive reduction of speed and motion amplitude
[47]. Bradykinesia is represented cranially by loss of facial
expression (hypomimia), decreased frequency of blinking,
monotonic and hypophonic speech, and drooling due to
decreased spontaneous swallowing. Other manifestations of
bradykinesia are slowness in raising from a chair, loss of
spontaneous gesturing, reduction of handwriting (micro-
graphia), reduced arm swing when walking, and reduced
gait amplitude and velocity [47]. Although both speed and
movement amplitude are affected in PD, the former is
usually disproportionally more affected in off state and less
normalized by levodopa than the latter, suggesting that they
may be associated with partially separate mechanisms [48].
The pathophysiology of bradykinesia is not completely
understood, but among PD cardinal signs, it is the one
that fits better with the classical model of the prevalence
of the indirect pathway over the direct one in the BG
(Figure 1) [14–16]. According to this model, failure of
the BG output to reinforce the cortical mechanisms may
involve the preparation of the movement or its execution
[14–16, 47].
Deficits in movement preparation in PD patients have
been documented by slower reaction times [49, 50] and
slower increase in premovement cortical excitability [51],
which together suggest abnormal retrieval of stored motor
commands [47]. EEG studies showed premovement potential
abnormalities [52], which were more marked in self-paced
versus externally triggeredmovements [53] and are consistent
with reduced activity in the supplementarymotor area during
movement programming [47]. EEG activity is physiologically
represented by predominant alpha (10Hz) and beta (20–
30Hz) range during motor inactivity and tonic position
holding and when stopping a preplanned movement, while
alpha and beta power is decreased ∼1 s before movement
[54]. Beta activity has been hypothesized to represent an
idle rhythm that favors the status quo over new movements
[55]. Premovement EEG beta desynchronization is reduced
in PD patients, and this abnormality is at least partially
normalized by dopaminergic stimulation [56]. Local field
potential recording in the BG indicates a coupling between
cortical and STN and GPi beta rhythms offmedication, while
they are decoupled on medication [57]. Beta band power
suppression to levodopa was demonstrated to correlate with
improvement in bradykinesia and rigidity but not tremor,
suggesting a specific pathogenetic significance [58]. In accor-
dance with these pieces of evidence, closed loop STN DBS,
where stimulation frequency is automatically adjusted online
according to the current state of the underlying network
activity, may offer advantages over current fixed frequency
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(usually 130Hz) DBS and its application could represent a
therapeutic advancement in PD [59].
Deficits in movement execution include difficulties in
producing maximal voluntary contraction [60] and abnor-
malities in the ballistic movement triphasic electromyo-
graphic pattern, which is composed of a first agonist muscle
burst, followed by a second antagonist muscle burst and
variably by a third agonist burst [47]. The size and duration
of the first agonist burst in PD patients are reduced and
suggest inappropriate scaling of the dynamic muscle force
to the required movement parameters [61]. PD patients have
additional difficulties represented by fatigue in complex or
repetitive movements, and this can be clinically assessed
when testing repetitive hand opening/closing or finger tap-
ping [62]. It has also been suggested that PD patients have
limited processing mechanisms that may interfere with their
ability to run complex or simultaneous tasks [63].
Abnormalities of cortical excitability [64, 65], somatosen-
sory function [66], and sensorimotor integration [67, 68]
and changes in the pattern of activation in the motor and
premotor cortices and the supplementary motor area [69, 70]
may also contribute to deficits in movement execution in PD
[47]. Whether these alterations represent true pathogenetic
mechanisms of bradykinesia or compensatory changes is still
unclear [64, 70, 71].
Secondary factors that may contribute to bradykinesia
include muscle weakness [60], rigidity [72], rest and action
tremor [73], and movement variability and bradyphrenia
[47].
6. Pathophysiology of Tremor in PD
PD patients can show different tremor types [74, 75]. They
include rest tremor, which stands among the PD cardinal
signs, especially in the tremor-dominant subtype [4, 40], an
action tremor named reemergent tremor, which reappears few
seconds after the transition from rest to posture and has a
frequency similar to that of rest tremor, essential tremor, dys-
tonic tremor [74], and exaggerated physiological tremor [75].
We will focus on the pathophysiology of rest tremor, which
is usually asymmetric with moderate amplitude, medium (4–
6Hz) frequency, and an agonist-antagonist alternate contrac-
tion pattern [76]. It typically involves the hand, manifesting
as a pill-rolling movement, and less frequently the forearm as
a pronation-supination, the leg as an adduction-abduction,
the jaw, and/or head as a yes-yes or no-no motion [76]. Rest
tremor is usually enhanced by motor or cognitive tasks and
not influenced by weighting [76].
The pathophysiology of rest tremor is largely unknown,
but there is good evidence that it differs from that of
bradykinesia and rigidity [77]. Rest tremor can be more
severe on the side opposite that of worse bradykinesia and the
magnitude of tremor is not related to dopamine deficiency
and does not respond readily to dopaminergic treatment
[75]. Some reports suggest a role of dopaminergic loss in the
midbrain retrorubral A8 field, which projects to the pallidum
and is separate from the nigrostriatal pathways, in the genesis
of rest tremor [32, 77]. The severity of rest tremor was
found to correlate with a decrease in median raphe serotonin
receptor binding [78], suggesting that serotoninergic rather
than dopaminergic neuron loss might bemore relevant to the
pathogenesis of this symptom, but this point is controversial
because serotoninergic drugs do not usually improve tremor
in PD [75].
Several hypotheses, which share the view of a central
rather than peripheral origin, have been suggested to explain
the pathophysiology of rest tremor [32]. Bursts that are
correlated with tremor have been demonstrated in a number
of cortical and subcortical areas, but the exact localization
of the primary tremor pacemaker is still debated [32, 76].
Thalamocortical relay neurons have ion channel properties
that support pacemaking at approximately rest tremor fre-
quency and may be modulated through hyperpolarization
by reducing excitatory drive or excitatory input from the
cerebellum [79]. Other models suggest a role of the recurrent
loop between GPe and the STN as the primary oscillator
[80] and the STN-cortical oscillatory coupling [81]. The
cerebellum seems to have a central role in PD tremor patho-
genesis, because rest tremor disappears following lesions of
the ventralis intermedius (VIM) thalamic nucleus, which
receives cerebellar input, and cerebellar stimulationmay alter
the timing of peripheral tremor. An emergent model indi-
cates abnormally synchronized BG-thalamocortical (BGTC)
loop, a GPe-STN pacemaker, and the cerebellar dentate-
thalamocortical (CTC) circuit as the main actors producing
rest tremor [32, 77]. According to this hypothesis, the GPe-
STN pacemaker and the BGTC loop trigger tremor episodes,
and theCTC circuitmaintains andmodulates their amplitude
[77]. This model is in accordance with the observation that
stereotactic lesions in selected areas of the BGTC (STN,
primary motor cortex, ventrolateral thalamic nucleus, and
pallidum) or the CTC (VIM) may abolish rest tremor
[77, 81].
7. Pathophysiology of Rigidity in PD
PD rigidity is characterized by increased muscle tone to
palpation at rest, reduced distension to passive movement,
increased resistance to stretching, and facilitation of the
shortening reaction [82]. Rigidity is more marked in flexor
than extensor muscles, may be enhanced by voluntary
movement of other body parts, and is more remarkable
during slow than fast stretching, and these features help
differentiating PD rigidity from spasticity, which is worse
during fast displacement [82, 83]. Cogwheel phenomenon is
the result of coexisting rigidity and tremor [82].
The pathogenesis of PD rigidity has been hypothesized
to include changes in the passive mechanical properties of
joints, tendons, and muscles, the enhancement of stretch-
evoked reflexes from segmental spinal or supraspinal activity,
and abnormalities in peripheral sensory inputs that may
influence the response to muscle stretch [83–86]. Studies on
spinal reflexes indicate a shift of spinal cord motoneurons
towards increased activity in response to peripheral stimula-
tion [84, 85] and increased response to muscle stretch [83],
with a possible contribution of transcortical long-latency
stretch reflex [86]. How these changes are associated with
dopamine deficiency and BGoutput abnormalities, which are
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stipulated by the classical BG pathophysiological model, is
still unclear [82].
8. Pathophysiology of
Motor Fluctuations and Dyskinesia
After several years of smooth and stable response to oral lev-
odopa treatment, PD patients invariably developmotor com-
plications, which include motor fluctuations and dyskinesia
[87, 88]. Motor fluctuations include wearing-off, delayed-
on, partial-on, no-on, and on-off fluctuations (Table 3)
[87]. Dyskinesia is choreic, ballistic, or dystonic involuntary
movements and can be classified into peak-dose, diphasic,
and square-wave dyskinesia (Table 3) [87]. Dystonia often
accompanies motor fluctuations and dyskinesia and may
appear in off and on phases (Table 3) [87].
The pathogenesis of motor complications is not com-
pletely understood, but central and peripheral mechanisms
have been suggested to contribute to motor fluctuations and
dyskinesia [88]. The main central mechanisms include (a)
the progression of nigrostriatal degeneration, which results
in the reduction of the capacity of storing dopamine in the
presynaptic vesicles and releasing them physiologically, (b)
enhanced conversion of levodopa to dopamine and aberrant
release in the striatum as false neurotransmitter by serotonin-
ergic neurons, (c) alterations in dopaminergic receptors that
undergo plastic changes, which include supersensitivity to
dopamine because of the loss of nigrostriatal projections,
desensitization, and downregulation because of the pres-
ence of nonphysiological high doses of dopamine, and (d)
increased glutamatergic activity in the striatum [87, 88].
The peripheral mechanisms encompass (a) reduced gastric
emptying that is related to PD autonomic dysfunction and
(b) competition of levodopa, which is a neutral aminoacid
and requires a carrier to pass the gut-blood and blood-brain
barriers, with other dietary amino acids after a protein-rich
meal [87]. The cumulative exposure to levodopa treatment,
which becomes necessary after a few years of PD disease
because of the limited therapeutic effect of dopamine ago-
nists, has been traditionally considered as a major player in
the pathogenesis of motor fluctuations and dyskinesia, which
are called levodopa-induced motor complications [87, 88].
A recent study on PD patients from a sub-Saharan African
country, where access to medication is limited, suggests that
motor complications are not associated with the duration
of levodopa therapy but rather with longer disease duration
and higher levodopa daily dose, arguing against the common
practice to delay levodopa treatment in favor of dopamine
agonists to delay the occurrence of motor complications [89].
Management strategies for motor complications and
dyskinesia include various pharmacological combined
approaches, such as fractionating levodopa by administering
small multiple daily doses, reducing the interval between
levodopa doses, adding controlled release, dispersible,
and soluble levodopa formulations, adding or increasing
dopamine agonists in particular controlled release and
transdermal formulations, monoamine oxidase-B inhibitors
or catechol-O-methyltransferase inhibitors, amantadine or
clozapine, botulinum toxin, subcutaneous apomorphine,
levodopa/carbidopa intestinal gel, and DBS (Table 3) [87].
Other strategies include adjusting protein intake throughout
the day, taking levodopa on an empty stomach, treating
constipation, tapering drugs that may interfere with gastric
emptying, and eradicating Helicobacter pylori (Table 3) [87].
9. Posture, Balance, and Gait Disturbances in
PD and Their Pathophysiology
Posture, balance, and gait disturbances are common in PD
and largely contribute to motor impairment, risk of falls,
and worse QoL [90, 91]. PD patients commonly show the
classic stooped appearance, with flexion of the hips and knees,
and rounding of the shoulders, but an important subset of
patients shows more severe postural deformities, including
camptocormia, antecollis, Pisa syndrome, and scoliosis [91,
92]. The pathophysiology of axial postural abnormalities in
PD is not well understood, and a number of central and
peripheral causes have been proposed, including asymmetry
of the BG outflow, rigidity, dystonia, abnormal processing
of vestibular or proprioceptive afferents, abnormal spatial
cognition, focal myopathy in the paraspinal muscles, spinal
and soft tissue changes, and side effects of dopaminergic
and nondopaminergic drugs [90, 92]. Because of the poor
knowledge on the pathogenesis of postural abnormalities,
their management is largely unsatisfactory, as they respond
poorly to medication, brain surgery, or physiotherapy [92].
Gait and balance disorders, which occur during the
course of PD, are a major problem and an unmet therapeutic
target, in that dopaminergic drugs and DBS often fail to
improve these signs and may worsen them in some cases
[91]. Gait is the result of dynamic interactions between
the activation of central movement programs and feedback
mechanisms [93]. Animal studies demonstrated the presence
of a spinal central pattern generator (CPG), which is con-
trolled by supraspinal centers [93]. Recent studies point to
a key role of the mesencephalic locomotor region (MLR),
which is located in the reticular formation and is composed
of the PPN and the cuneiform nucleus, for the control of
gait and balance in humans [93, 94]. TheMLR has reciprocal
connectionswith the BG, receives inputs from the cerebellum
and motor cortices, and has outputs to the descending
reticulospinal pathway and the ascending thalamocortical
pathway through the thalamic centromedian nucleus [91].
The spinal CPG and the MLR are under cortical control [93].
An indirect pathway from the frontal cortex via the BG to
the MLR allows modulation of the gait pattern in response to
external demands [95]. A direct pathway from the primary
motor cortex to the spinal CPG can bypass the MLR during
undisturbed locomotion [95]. Input from the cerebellum
conveys both pathways in the MLR to control speed and gait
pattern, according to proprioceptive, vestibular, and visual
information [93, 95]. Given the complex anatomy underlying
locomotion, gait and balance signs may be heterogeneous
in PD patients [91]. In early PD, hypokinetic gait, which
is characterized by reduced gait speed and amplitude with
nearly normal cadence, is an expression of the bradykinesia
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and is related to a deficit in internal generation of adapted
step length [96]. In line with this concept, hypokinetic gait
may be ameliorated by dopaminergic treatment and external
visual cues [91].The characterization of gait problems is more
complex in later PD stages, when changes in multiple neural
systems may contribute to them [21, 91, 97]. In advanced
PD patients, gait is clearly abnormal, but it is often difficult
to distinguish between the specific contribution of sensory,
motor, and cognitive (i.e., executive functions and attention)
deficits and factors like fear, imbalance, muscle weakness,
loss of basic locomotion rhythmicity, and misjudgment of
hazard risk [97]. In later PD, different neurotransmitters
have been hypothesized to contribute to gait disturbance,
including noradrenalin and serotonin systems, but converg-
ing evidence points to a key role of cholinergic dysfunction in
the PPN [21, 42, 43, 94]. According to this view, some reports
showed improvement of PD gait disturbances to inhibitors
of cholinesterase [21, 43]. Despite these results needing to
be replicated in more robust studies, this pharmacological
strategy should not be discarded [91]. Bilateral PPN low
frequency DBS was suggested to effectively control gait and
balance disorders in small samples of patients, but these
preliminary data were not confirmed by two RCTs [98],
suggesting that better criteria for selecting patients and for
optimal targeting within the MLR are needed [91].
10. Pathophysiology of Freezing of Gait
Freezing of gait (FOG) is an episodic gait disturbance [97],
which is characterized by difficulty in gait initiation (start
hesitation) and paroxysmal unintentional episodes of motor
block during walking [99]. A FOG episode can manifest
with step size reduction (shuffling gait), knee trembling, or
akinesia and is typically described as feeling the feet as frozen
or glued to the ground [100]. FOG is often triggered or wors-
ened by challenging situations or provocative environments,
such as changing direction (turning hesitation), approaching
narrow doorways (tight quarter hesitation) or destinations
(destination hesitation), moving into crowded spaces, walking
on a slippery surface, crossing thresholds or changes in
floor, stepping into an elevator, or entering a revolving
door [100]. Furthermore, freezing episodes can occur when
patients are required to deal with simultaneous activities
(dual tasking), like walking and talking [99, 101]. Emotional
factors such as stress or anxiety may also contribute to
triggering FOG episodes [100]. All the above circumstances
require a dynamic adaptation of motor schema, because of
an increased cognitive load [100, 101]. Different subtypes of
FOG are defined according to clinical manifestations and
response to external stimuli (e.g., visual or auditory cues) and
to levodopa [100]. It has long been observed that freezing
phenomena in PD patients are responsive to visual cues, such
as stepping over a small obstacle (e.g., a foot or a laser on the
cane/walker), or auditory cues, such as following a rhythm
(e.g., counting, listening to a metronome or music) to step
to the beat, and this clinical observation offers a rationale for
some rehabilitation strategies for FOG [91]. FOG is common
in advanced PD and is associated with increased risk of falls
and reduced mobility and QoL [102].
The neuropharmacological bases of FOG are poorly
understood [99, 100]. Despite being common in advanced PD
patients, FOG may appear early in the disease course [100].
Moreover, the response of FOG to dopaminergic therapy
and DBS may be poor, and this clinical phenomenon is
not unique to PD [100]. These observations suggest that
severe dopamine depletion alone could not explain FOG
and critical brain regions for this phenomenon should differ
from those involved in cardinal PD features [94, 100]. As for
other gait disturbances in PD, cholinergic loss in the PPN,
which stands at the crossroad between supraspinal and spinal
gait centers, may play a role in FOG [93, 94]. In keeping
with this hypothesis, bilateral DBS of the caudal PPN may
improve FOG [103]. Cortical cholinergic loss and amyloid
deposition [104] and gray matter atrophy in the inferior
parietal lobe and angular gyrus [105] may also contribute to
FOG pathophysiology.
There are several theories regarding the occurrence of
FOG [100, 106]. Based on the association between its occur-
rence and some visual stimuli, such as passing through
a narrow space, FOG has been suggested to depend on
impaired visuospatial ability that interfereswith onlinemove-
ment planning [106, 107]. Visuospatial tests may discriminate
freezers from nonfreezers and their deficits are strongly
related with FOG severity andmetrics [108], but other studies
contradicted the notion that the lack of visuospatial ability
per se may be primarily responsible for FOG [107, 109].
Impaired coupling between postural control and step
initiation has also been hypothesized to contribute to FOG,
because of its strong correlation with postural instability
[100]. While a single anticipatory postural correction that
shifts weight off the stepping leg precedes a voluntary step
in normal gait, PD patients with FOG show delayed step
initiation associated with repetitive anticipatory postural
adjustments, as if they cannot inhibit their postural prepa-
ration and release the stepping program [110].
The hypotheses on FOG pathophysiology have recently
shifted towards a multisystem dysfunction, where cognition
plays a significant role [101, 111]. Although gait has been long
considered a low-level automatedmotor activity that requires
minimal higher cortical functions, growing evidence suggests
a role for cognition, especially attention and executive func-
tions in gait control [99].Differentmodels, which incorporate
cognition in the pathogenesis of FOG, have been recently
proposed and some of them will be briefly reviewed [111].
According to the interference model, FOG is the con-
sequence of concurrent cognitive overload during walking
[112]. This model suggests that reduced neural reserve in the
BG leads to communication breakdownbetweenmotor, asso-
ciative, and limbic parallel circuits causing abnormal pallidal
output and temporary interruption of gait pathways [112].
Because of reduced automaticity in PD, there is an overload of
systems involved in performing voluntary actions, especially
when patients are asked to perform a dual task [99, 101].
According to this hypothesis, during a virtual reality gait task
where the cognitive load was manipulated, PD patients with
FOG demonstrated functional decoupling between the BG
and the cognitive control networks in association with the
occurrence of paroxysmal motor arrests [113].
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The cognitive model stipulates that impaired decision
making because of executive dysfunction [114] leads to
stronger automatic activation of incorrect responses and
less efficient suppression of conflicting responses and results
in delayed response selection and FOG [111]. Executive
functions are an umbrella term for a set of abilities, which are
involved in inhibition, switching, and updating, and flexibly
control behavior towards goals [115, 116]. Among executive
functions, difficulties in set shifting have stronger association
with the presence of FOG [113]. The frontostriatal circuits
are central for action selection and response inhibition,
in signaling conflict and temporarily preventing premature
action by raising the decision threshold, such that response
selection is delayed until conflict is resolved [117]. A growing
body of evidence suggests that cognitive impairment, in
particular executive dysfunction, often coexists with posture
and gait abnormalities, FOG, and risk of falls in PD, but their
interplay appears to be complex [118] and may represent a
promising basis for new rehabilitative approaches to treat gait
disturbances in PD patients [99].
11. Fatigue and Pain in PD
Fatigue is defined as an overwhelming sense of tiredness,
lack of energy, and feeling of exhaustion, with difficulties
in initiating and sustaining mental and physical tasks in
the absence of motor or physical impairment and consist-
ing of a mental and physical component [119, 120]. The
pathophysiology of PD-related fatigue appears to be complex,
in that it involves both motor and nonmotor mechanisms,
which depend on the involvement of nondopaminergic and
extrastriatal dopaminergic pathways [119].
PD patients often complain of pain, which may be
associated or not with the presence of dystonia in the same
body regions affected by pain [121]. Experimental evidence
suggests the presence of abnormal processing of nociceptive
afferents in pain pathways, independently of dystonia and
motor disturbances in PD [122, 123].
Despite not representing motor disturbances, fatigue
and pain may negatively influence motor performances in
PD [120]. Some reports suggested that caffeine [46] and
monoamine oxidases inhibitors alone or in combination
with antidepressants [124] may improve fatigue in PD and
that opioids might be effective for some subtypes of PD-
related pain [125]. Despite these recent advancements, pain
and fatigue are two symptoms that are underrecognized and
with no established therapy in PD, and they may represent
interesting targets for nonpharmacological treatments, such
as aerobic exercise [126] or rehabilitation procedures.
12. Depression, Apathy, and Cognitive
Problems in PD
Depression, apathy, and cognitive deficits are common in
PD patients and may sometimes overlap and interact [127].
Despite the fact that they can have a negative effect on QoL
and the functioning of PDpatients, as well as reduced compli-
ance to pharmacological and nonpharmacological treatment,
they are often underrecognized and undertreated [127, 128].
Depression may affect 50–70% of PD patients, is a
multifactorial condition, which depends upon degeneration
of noradrenaline and serotonin neurons, and represents a
reactive condition to PD [129]. Pharmacologic treatment
with antidepressant medications, specifically the selective
serotonin reuptake inhibitors, and cognitive behavioral inter-
ventionsmay significantly improve depression in PD patients
[129].
Apathy is defined as lack of motivation characterized
by diminished goal-oriented behavior and cognition and
reduced emotional expression [26, 128]. Although apathy can
occur as a symptom of depression, it may represent a separate
phenomenon in PD [130]. While depression is a highly nega-
tive affective experience, apathy is characterized by complete
affective flattening in the absence of sadness [26]. However, in
the clinical setting, separating depression from apathy is often
not a straightforward task [26, 128]. Up to 40% of PD patients
suffer from apathy, which is more common in older men with
more severemotor impairment, worse executive dysfunction,
and a higher risk of developing dementia [130]. Apathy in
PD is caused by a dysfunction or neuronal loss in a complex
neural network, which is not limited to the limbic loop of the
BG, but includes the mesocorticolimbic pathway, the caudate
nucleus, the lateral prefrontal cortices, the inferior medial
frontal gyrus, the cingulate cortex, the insula, the cuneus, and
the temporoparietal region [131, 132].The treatment of apathy
in PD is currently controversial, but there is a good rationale
for the use of dopaminergic drugs to improve the emotional
and behavioral aspects and for cholinesterase inhibitors to
treat the cognitive aspects of apathy [26, 133].
Cognitive deficits may affect every cognitive domain,
including memory, language, attention, visuospatial abili-
ties, and executive functions, with the latter showing the
most profound impairment [134]. The spectrum of cognitive
dysfunction in PD ranges from mild cognitive impairment
(MCI) to dementia, withMCI representing a transitional state
between normal cognition and dementia [7, 135] The recent
introduction of diagnostic criteria for PD-related MCI [135]
is important for its early recognition and treatment [7].
13. Rehabilitation Procedures in
PD and Their Pathophysiological Grounds
Despite optimal medical treatment and neurosurgical inter-
ventions, PD patients develop progressive disability [136].
The role of rehabilitation in PD is to maximize motor
and cognitive functional abilities and minimize secondary
complications in order to optimize independence, safety, and
well-being, thus enhancing QoL [137]. Several rehabilitative
approaches have been proposed in PD, including nonspecific
physiotherapy (i.e., muscle strengthening and stretching,
balance, and postural exercises) [138, 139], occupational
therapy [140], treadmill and robotic training [141–145], dance
and martial arts therapy [146], multidisciplinary approaches
including speech and cognitive therapy [8, 147, 148], motor
imagery and action observation therapy [137, 149], and virtual
reality and telerehabilitation [150]. There is evidence that
physiotherapy causes short-term, significant, and clinically
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important benefit for walking speed, balance, and clinician-
rated disability in PD [138], but it is insufficient to support or
refute the superiority of an intervention over another because
of the small number of patients examined by previous studies,
the methodological flaws, and the variety of the approaches
that have been proposed [137]. However, exercise is generally
accepted as an intervention that could ameliorate motor and
nonmotor PD symptoms and should be considered as the
basic element of any rehabilitative treatment in PD patients
[126, 137].
The principles of neuromechanics are a framework for
understanding the patterns of neural activity that generate
movements in healthy people and are important for the
rehabilitation of patients with motor deficits [151]. Together
with neural plasticity, they support the development of
motor modules, which have been defined as coordinated
patterns of muscle activity flexibly combined to produce
functional motor behaviors [151].The neuromechanical prin-
ciples include motor abundance (i.e., for any given task, there
are many functionally equivalent motor solutions), motor
structure (i.e.,motormodules reflect biomechanical task rele-
vance),motor variability (i.e.,motormodule variations across
individuals are high if the effect on motor output is low),
individuality (i.e., individuals express different motor styles
that depend on evolutionary, developmental, and learning
processes), andmultifunctionality (i.e., muscle activity can be
combined in many ways to produce a wide range of different
actions) [151].
BG loops have been hypothesized to contribute to
choosing the desired motor output and selectively inhibiting
competing motor programs [152] and to be involved in
reward prediction and habit formation [153, 154]. In PD,
the BG dysfunction is supposed to lead to inappropriate
selection of motor modules [151, 152]. Upon these premises,
PD rehabilitation procedures are aimed to improve the
appropriate recruitment of motor modules through exercise
and practice of complex tasks according to a goal-based
learning approach, which involves planning and execution
of composite and/or unfamiliar movements (e.g., backward
walking) [137, 151].
Motor rehabilitation may be regarded as a process of
motor relearning through practice and training [155]. The
acquisition ofmotor skills is supposed to go through different
phases (i.e., fast, slow, consolidation, reconsolidation, autom-
atization, and retention), which differentially involve the
corticostriatal and corticocerebellar pathways and depend
upon online and offline triggered plastic changes in the
brain [156]. PD patients show preserved ability in motor
learning [155], but BG dysfunction may impair consolidation
of learned material, and translation to the clinical setting
may be critical [137]. Along this line, reduced experience-
dependent neuroplasticity, which is largely influenced by
intensity, repetition, specificity, difficulty, and complexity of
practice, may represent a crucial issue in PD [137]. Motor
cortical plasticity may be a compensatory change that con-
tributes to delaying motor signs onset in the early phases of
PD, but it deteriorates as the disease progresses [157].
Other largely unexplored mechanisms involved in PD
rehabilitation include focusing on external cues to bypass the
dysfunctional BG activity and access the corticocerebellar
pathways [158], enhancing cognitive engagement through
problem solving, attentional demand and motivation [137],
and aerobic training to increase cardiopulmonary function,
oxygen consumption, and blood flow to the brain [159].
14. Conclusions and Future Perspectives
This brief review summarized the current hypotheses on
the pathophysiology of motor dysfunction in PD. The neu-
ropathological, neurochemical, and neurophysiological bases
of PD motor symptoms offer the rationale for current phar-
macological and nonpharmacological treatment of this con-
dition but may also represent the bases for future strategies
for managing this condition [21, 137]. Future studies aimed at
a better understanding of PD pathophysiology will offer the
premises for new pharmacological strategies [21], as well as
new targets for DBS [59, 87, 98] and rehabilitation procedures
[160], and to achieve a personalizedmedicine approach to PD
based on biomarkers [161].
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